[go: up one dir, main page]

MX2008002062A - Uso de derivados de tienopiridona como activadores de ampk y composiciones farmaceuticas que los contienen. - Google Patents

Uso de derivados de tienopiridona como activadores de ampk y composiciones farmaceuticas que los contienen.

Info

Publication number
MX2008002062A
MX2008002062A MX2008002062A MX2008002062A MX2008002062A MX 2008002062 A MX2008002062 A MX 2008002062A MX 2008002062 A MX2008002062 A MX 2008002062A MX 2008002062 A MX2008002062 A MX 2008002062A MX 2008002062 A MX2008002062 A MX 2008002062A
Authority
MX
Mexico
Prior art keywords
pharmaceutical compositions
compositions containing
ampk activators
thienopyridone derivatives
thienopyridone
Prior art date
Application number
MX2008002062A
Other languages
English (en)
Inventor
Bjoern Hock
Sophie Hallakou-Bozec
Christine Charon
Oliver Poeschke
Original Assignee
Merck Patent Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Patent Gmbh filed Critical Merck Patent Gmbh
Publication of MX2008002062A publication Critical patent/MX2008002062A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4436—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/64—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Diabetes (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Uso de derivados de tienopiridona de la formula (I): (ver formula (I)) en donde B, R, R6, Y y Z son como se definen en la descripcion, y sus sales farmaceuticamente aceptables, para la preparacion de una composicion farmaceutica util para el tratamiento de diabetes, sindrome metabolico, trastornos relacionados y obesidad.
MX2008002062A 2005-08-18 2006-07-03 Uso de derivados de tienopiridona como activadores de ampk y composiciones farmaceuticas que los contienen. MX2008002062A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP05291753A EP1754483A1 (en) 2005-08-18 2005-08-18 Use of thienopyridone derivatives as AMPK activators and pharmaceutical compositions containing them
PCT/EP2006/006446 WO2007019914A1 (en) 2005-08-18 2006-07-03 Use of thienopyridone derivatives as ampk activators and pharmaceutical compositions containing them

Publications (1)

Publication Number Publication Date
MX2008002062A true MX2008002062A (es) 2008-04-16

Family

ID=35636709

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2008002062A MX2008002062A (es) 2005-08-18 2006-07-03 Uso de derivados de tienopiridona como activadores de ampk y composiciones farmaceuticas que los contienen.

Country Status (20)

Country Link
US (1) US20090105293A1 (es)
EP (2) EP1754483A1 (es)
JP (1) JP5161774B2 (es)
KR (1) KR20080034491A (es)
CN (1) CN101232883A (es)
AT (1) ATE496622T1 (es)
AU (1) AU2006281761B2 (es)
BR (1) BRPI0614828A2 (es)
CA (1) CA2619505C (es)
CY (1) CY1111660T1 (es)
DE (1) DE602006019880D1 (es)
DK (1) DK1915150T3 (es)
ES (1) ES2359860T3 (es)
MX (1) MX2008002062A (es)
PL (1) PL1915150T3 (es)
PT (1) PT1915150E (es)
RU (1) RU2416409C2 (es)
SI (1) SI1915150T1 (es)
WO (1) WO2007019914A1 (es)
ZA (1) ZA200802454B (es)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102005017152B4 (de) * 2005-04-13 2007-02-08 Lindauer Dornier Gmbh Verfahren zum Trocknen von vorzugsweise plattenförmigen Produkten und Durchlauftrockner in Mehretagenbauweise
CN101854933A (zh) 2007-09-10 2010-10-06 钙医学公司 调节细胞内钙的化合物
HRP20160907T1 (hr) * 2008-04-11 2016-09-23 Merck Patent Gmbh Derivati tienopiridona kao aktivatori amp-aktivirane protein kinaze (ampk)
NZ589690A (en) * 2008-05-05 2012-07-27 Merck Patent Gmbh Thienopyridone derivatives as AMP-activated protein kinase (AMPK) activators
GB0813403D0 (en) 2008-07-22 2008-08-27 Lectus Therapeutics Ltd Potassium ion channel modulators & uses thereof
CA2734500A1 (en) * 2008-08-27 2010-03-11 Calcimedica Inc. Compounds that modulate intracellular calcium
US8524763B2 (en) 2008-09-22 2013-09-03 Calcimedica, Inc. Inhibitors of store operated calcium release
WO2010103040A1 (en) 2009-03-10 2010-09-16 INSERM (Institut National de la Santé et de la Recherche Médicale) 5'-adenosine monophosphate-activated protein kinase (ampk) activators for treating pulmonary hypertension
KR101062670B1 (ko) * 2009-06-01 2011-09-06 (주)아모레퍼시픽 2,5-비스-아릴-3,4-디메틸테트라하이드로퓨란 리그난을 유효성분으로 포함하는 에이엠피케이의 활성화에 의해 매개되는 비만 관련 질환의 예방 또는 치료용 조성물
WO2011034962A2 (en) 2009-09-16 2011-03-24 Calcimedica Inc. Compounds that modulate intracellular calcium
CN102666485A (zh) * 2009-09-21 2012-09-12 霍夫曼-拉罗奇有限公司 烯烃羟吲哚衍生物及其用于治疗肥胖症，糖尿病和高脂血症的应用
EP2552435A1 (en) 2010-04-02 2013-02-06 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and compositions comprising ampk activator (metformin/troglitazone) for the treatment of myotonic dystrophy type 1 (dm1)
MX337711B (es) 2010-08-27 2016-03-15 Calcimedica Inc Compuestos que modulan el calcio intracelular.
CN103189376B (zh) 2010-09-01 2016-02-24 拜耳知识产权有限责任公司 具有除草活性的酮基磺内酰胺和二酮基吡啶
US9005909B2 (en) 2011-01-06 2015-04-14 Rigel Pharmaceuticals, Inc. Whole blood assay for measuring AMPK activation
EP2683690A1 (en) * 2011-03-07 2014-01-15 GlaxoSmithKline LLC Quinolinone derivatives
US8889730B2 (en) 2012-04-10 2014-11-18 Pfizer Inc. Indole and indazole compounds that activate AMPK
EP2679591A1 (en) 2012-06-29 2014-01-01 Poxel Thienopyridone derivatives useful as activators of AMPK
WO2014059333A1 (en) 2012-10-12 2014-04-17 Calcimedica, Inc. Compounds that modulate intracellular calcium
JP6064062B2 (ja) 2013-03-15 2017-01-18 ファイザー・インク Ａｍｐｋを活性化させるインダゾール化合物
WO2015103480A1 (en) 2014-01-02 2015-07-09 Massachusetts Eye & Ear Infirmary Treating ocular neovascularization
CN105315275B (zh) * 2014-07-14 2019-10-01 中国科学院上海药物研究所 一类吡唑酮化合物及其用途
US20190054096A1 (en) 2015-09-30 2019-02-21 Instituto De Medicina Molecular Methods for attenuating parasite virulence
US20190350955A1 (en) 2016-06-30 2019-11-21 Inserm (Institut National De La Sante Et De La Recherche Medicale Methods and pharmaceutical compositions for the treatment of cardiomyopathies
RU2766146C2 (ru) * 2016-10-05 2022-02-08 Юниверсити Оф Питтсбург - Оф Дзе Коммонвелт Систем Оф Хайер Эдьюкейшн Низкомолекулярные активаторы амфк
WO2018156459A1 (en) * 2017-02-22 2018-08-30 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Compounds and methods for inhibiting emt pathways to treat cancer, organ fibrosis and metabolic disorders
CN113166168A (zh) * 2018-11-16 2021-07-23 博希尔公司 噻吩并吡啶酮衍生物的一水合钾盐及其制备方法
WO2020201263A1 (en) 2019-04-01 2020-10-08 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for the treatment and prevention of cardiac remodeling
EP4027987A4 (en) 2019-09-10 2023-11-29 University of Pittsburgh - Of the Commonwealth System of Higher Education Methods and materials for increasing level of phosphorylated ampk protein
WO2022106892A1 (en) 2020-11-17 2022-05-27 Instituto De Medicina Molecular Anti-malarial compounds
EP4433458A4 (en) 2021-11-19 2025-10-29 Broad Inst Inc Bifunctional chimeric molecules for labeling kinases with target bond fractions and their methods of use

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2358150A1 (fr) * 1976-07-13 1978-02-10 Parcor Nouvelles thieno (2,3-c) et (3,2-c) pyridines, leur procede de preparation et leur application
GB8625941D0 (en) * 1986-10-30 1986-12-03 Sandoz Ltd Substituted alpha-amino acids
DE4444815A1 (de) 1994-12-15 1996-06-20 Merck Patent Gmbh Thienopyridone
FR2846656B1 (fr) 2002-11-05 2004-12-24 Servier Lab Nouveaux derives d'imidazopyridine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
US7119205B2 (en) 2003-05-16 2006-10-10 Abbott Laboratories Thienopyridones as AMPK activators for the treatment of diabetes and obesity
JP2005089384A (ja) 2003-09-18 2005-04-07 Kao Corp 持久力向上剤

Also Published As

Publication number Publication date
JP5161774B2 (ja) 2013-03-13
PT1915150E (pt) 2011-05-02
CY1111660T1 (el) 2015-10-07
ATE496622T1 (de) 2011-02-15
EP1915150B1 (en) 2011-01-26
CN101232883A (zh) 2008-07-30
ZA200802454B (en) 2009-01-28
SI1915150T1 (sl) 2011-04-29
ES2359860T3 (es) 2011-05-27
WO2007019914A1 (en) 2007-02-22
AU2006281761A1 (en) 2007-02-22
PL1915150T3 (pl) 2011-05-31
CA2619505A1 (en) 2007-02-22
DE602006019880D1 (de) 2011-03-10
DK1915150T3 (da) 2011-02-21
KR20080034491A (ko) 2008-04-21
RU2008109914A (ru) 2009-09-27
AU2006281761B2 (en) 2012-01-19
US20090105293A1 (en) 2009-04-23
RU2416409C2 (ru) 2011-04-20
EP1754483A1 (en) 2007-02-21
EP1915150A1 (en) 2008-04-30
CA2619505C (en) 2015-04-28
BRPI0614828A2 (pt) 2011-04-19
JP2009504693A (ja) 2009-02-05

Similar Documents

Publication Publication Date Title
MX2008002062A (es) Uso de derivados de tienopiridona como activadores de ampk y composiciones farmaceuticas que los contienen.
IL187005A0 (en) Diacylglycerol acyltransferase inhibitors
SG155961A1 (en) Pyrazoles as 11-beta-hsd-1
WO2007060140A3 (en) Inhibitors of diacyglycerol acyltransferase (dgat)
MX2007010532A (es) Derivados de amida de acido 1-sulfonil-piperidina-3-carboxilico como inhibidores de 11-beta-hidroxiesteroide deshidrogenasa para el tratamiento de diabetes mellitus tipo ii.
WO2007082808A3 (en) Thiazoles as 11 beta-hsd1 inhibitors
MX2009012285A (es) Inhibidores de diacilglicerol aciltransferasa.
WO2009010416A3 (en) Inhibitors of 11b-hydroxysteroid dehydrogenase
MX2009006474A (es) Derivados de benzamida como agonistas del receptor ep4.
NO20074872L (no) Pyrazoler
SE0202463D0 (sv) Novel compounds
NO20082445L (no) Neuropeptid-2 reseptor-agonister
UA94065C2 (en) Dihydropseudoerythromycin derivatives
MX2009013501A (es) Compuestos piperidinicos y sus usos.
WO2010052144A3 (en) Neuropeptide-2-receptor (y-2r) agonists and uses thereof
MY143568A (en) 11b-hsd1 inhibitors for the treatment of diabetes
WO2006077025A3 (en) Morpholines as 5ht2c agonists
NO20065880L (no) 3-Amino-l-arylpropylindoler som monoamin-gjenopptagelsesinhibitor
MX2009003169A (es) Derivados de sulfonamida.
MX2007003913A (es) Alquil-piridinas como inhibidores de 11 beta para diabetes.
TW200639156A (en) New compounds
NO20080669L (no) Acetylenpiperaziner som metabotrofiske glutamatreseptorantagonister
NO20080671L (no) Bisykliske piperaziner som metabotrofiske glutamatreseptorantagonister
MX2009013003A (es) Derivados de piperidina-amida.
TW200800993A (en) Organic compounds

Legal Events

Date Code Title Description
FG Grant or registration